左旋精氨酸对低氧性肺动脉高压治疗作用的实验研究

目的：探讨结构型一氧化氮合酶（ｃＮＯＳ）,内皮素－１（ＥＴ－１）在低氧性肺动脉高压（ＨＰＨ）发病中的机制及左旋精氢酸（Ｌ－Ａｒｇ）对ＨＰＨ的治疗作用。方法：３０只健康雄性ＳＤ大鼠平均分为三组：正常对照组（ＮＣ组）、低氧组（ＨＰ组）、低氧左旋精氨酸治疗组（ＬＴ组）。后组每日低氧前给予２００ｍｇ／ｋｇ Ｌ－Ａｒｇ。于低氧２１ｄ检测运动血流动力学,肺组织ＮＯ、ＥＴ－１含量,肺动脉内皮ｃＮＯＳ含量的改变,     

NO—样松弛因子对止血带休克大鼠血管舒缩活动的影响

本工作在大鼠止血带休克（ＴｏＳ）模型上观察ＮＯ前体Ｌ－精氨酸Ｌ－Ａｒｇ,ＮＯ合成阻断剂Ｌ－ＮＮＡ及可溶性鸟苷酸环化酶抑制剂亚甲兰（ＭＢ）对离体胸主动脉舒缩活动的影响。发现止血带休克大鼠离体灌流的主动脉对去甲肾上腺素的反应性降低。血管组织ｃＧＭＰ含量增加。Ｌ－Ａｒｇ可增强这一变化,而Ｌ－ＮＮＡ或ＭＢ可减轻上述变化,而且这些药物作用不受血管内皮是否存在的影响。实验结果提示,非内皮细胞源的ＮＯ－样松弛因子（ＮＯ－ＬＲＦ）是引起止血带休克动物血管低反应性的因素之一     

肾上腺髓质素（13—52）降压机制的探讨

本工作在整体和离体大鼠模型上观察肾上腺髓质素（１３－５２）［ＡｄＭ（１３－５２）］的降压机制,发现ＡｄＭ（１３－５２）的降压作用可被一氧化氮合酶（ＮＯＳ）竞争性拮抗剂Ｌ－Ｎ－硝基－精氨酸？（ＬＮＮＡ）部分抑制;ＡｄＭ１３－５２）的舒血管作用依赖于血管内皮并可被ＬＮＮＡ抑制,且具有剂量效应,ＬＮＮＡ这种效应可被Ｌ－精氨酸（ＬＡｒｇ）逆转;用亚甲蓝（ＭＢ）阻断血管内的环－磷酸鸟苷酸（ｘＧＭＰ）,则导致     

一氧化氮和前列腺素在内毒素引起降钙素基因相关肽释放中的作用

本实验在离体灌流大鼠肠系膜动脉床研究内毒素引起降钙素基因相关肽（ＣＧＲＰ）释放的机制。内毒素（５０μｇ／ｍｌ）使ＣＧＲＰ释放增加１６倍,一氧化氮合成酶（ＮＯＳ）底物Ｌ－精氨酸（Ｌ－Ａｒｇ）能促进内毒素引起的ＣＧＲＰ释放（４１％）。ＮＯＳ抑制剂Ｎ￣Ｇ－硝基－Ｌ－精氨酸（Ｌ－ＮＮＡ）及鸟苷酸环化酶抑制剂甲基蓝（ＭＢ）能使内毒素的上述作用分别降低３５％与３６％,Ｌ－精氨酸（ｔ－Ａｒｇ）能逆转Ｌ－ＮＮＡ的作用。提示内毒素的作用机制中部分是通过一氧化氮引起细胞内ｃＧＭＰ升高而介导的。用化学方法破坏血管内皮细胞,Ｌ－ＮＮＡ与Ｌ－Ａｒｇ的上述作用依然存在。提示内毒素主要是激活血管周围感觉神经末梢的神经源ＮＯＳ,而非内皮源ＮＯＳ。环氧化酶抑制剂消炎痛（Ｉｎｄｏ）与布洛芬（Ｉｂｕ）也能使内毒素引起ＣＧＲＰ释放的作用分别降低３４％与３９％,但与Ｌ－ＮＮＡ的作用不能迭加。提示内毒素可能通过激活神经源ＮＯＳ进而引起环氧化酶活化而起作用。     

肾上腺髓质素（13－52）降压机制的探讨

本工作在整体和离体大鼠模型上观察研究了肾上腺髓质素（１３－５２）［ＡｄＭ（１３－５２）］的降压机制,发现ＡｄＭ（１３－５２）的降压作用可被一氧化氮合酶（ＮＯＳ）的竟争性桔抗剂Ｌ－ＮＧ－硝基－精氨酸（ＬＮＮＡ）部分抑制;ＡｄＭ（１３－５２）的舒血管作用依赖于血管内皮并可被ＬＮＮＡ抑制,且具有剂量效应关系,ＬＮＮＡ的这种效应可被Ｌ－精氨酸（Ｌ－Ａｒｇ）逆转;用亚甲蓝（ＭＢ）阻断血管内的环－磷酸鸟苷酸（ｃＧＭＰ）,则导致ＡｄＭ（１３－５２）的舒血管作用消失;放免测定显示ＬＮＮＡ可以降低血管内ｃＧＭＰ含量,而ＡｄＭ（１３－５２）则使后者含量增加,这一现象在ＡｄＭ（１３－５２）与ＬＮＮＡ合用时消失。实验结果提示,ＡｄＭ（１３－５２）的舒血管降血压效应与ＮＯ有关,可能是通过ＮＯ介导的。     

NO对大鼠睡眠-觉醒的调节

目的和方法：通过对大鼠侧脑室微量注射ＮＯＳ抑制剂Ｌ－ＮＡＭＥ及ＮＯ的前体Ｌ－精氨酸（Ｌ－Ａｒｇ）观察两种物质对大鼠睡眠－觉醒的影响。结果：注射１ｍｇ Ｌ－ＮＡＭＥ（５μＬ）后４ｈ觉醒（Ｗ）明显增加,尤以注射后第１￣２ｈ显著;４ｈ慢波睡眠（ＳＷＳ）明显减少,该效应同样以注射后第１￣２ｈ显著;异相睡眠（ＰＳ）无明显变化。小剂量Ｌ－ＮＡＭＥ（０．２ｍｇ,５μｌ）对大鼠的Ｗ、ＳＷＳ、ＰＳ无明显影响;同样方     

缺氧复氧对家兔胸主动脉环张力的影响及其机制

生物测定法观察家兔胸主动脉环经缺氧－复氧后血管张力的变化及这种变化与内皮的关系,并初步探讨了缺氧复氧对血管张力影响的机制。结果表明急剧缺氧可使苯肾上腺素（ＰＥ）预收缩的主动脉环出现短暂的收缩,随即自发舒张,复氧后立即舒张,随后持续收缩;去除内皮或经一氧化氮（ｎｉｔｒｉｃｏｘｉｄｅ,ＮＯ）合成酶抑制剂Ｎ－硝基－精氨酸－甲基酯（Ｌ－ＮＡＭＥ）或鸟苷酸环化酶抑制剂美蓝（ＭＢ）孵育后的血管环,缺氧性收缩反应消除或明显抑制,复氧性舒张也受到明显抑制,而复氧性收缩显著增强;加入ＮＯ合成底物Ｌ－精氨酸（Ｌ－Ａｒｇ）孵育后,有内皮血管环缺氧复氧性张力变化与对照组相比无明显变化。表明缺氧性血管收缩是内皮依赖性的,与ＮＯ释放的迅即减少有关;复氧早期引起的舒张是由于内皮释放ＮＯ引起的,而随后的收缩可能因复氧后大量氧自由基灭活ＮＯ所致。     

蛋白激酶C在血管紧张素Ⅱ抑制心肌细胞——氧化氮合成中的作用

实验用硝酸还原酶法测定培养新生大鼠内肌细胞亚硝酸盐（ＮＯ２）和硝酸盐（ＮＯ３）总量（ＮＯ２／ＮＯ３）,反映心肌细胞一氧化氮（ＮＯ）生成情况,观察血管紧张素Ⅱ（ＡｎｇⅡ）对凡肌细胞ＮＯ生成的及其蛋白激酶Ｃ（ＰＫＣ）在该效应中的作用。结果显示：ＡｎｇⅡ可减少心肌细胞ＮＯ的含量,并具有明显的剂量－效应关系;ＡｎｇⅡ受体拮抗剂ｓａｒａｌａｓｉｎ可明显抵制ＡｎｇⅡ对ＮＯ生成的影响;Ｌ－精氨酸（Ｌ－Ａｒｇ）明     

运动对大鼠血小板L—精氨酸转运的影响

本工作在游泳大鼠模型上,观察血小板Ｌ－精氨酸（Ｌ－Ａｒｇ）转运特征,并观察凝血酶和ＰＡＦ对血小板Ｌ－Ａｒｇ转运的影响。结果发现,运动大鼠血小板Ｌ－Ａｒｇ转运明显高于未运动对照大鼠,表现在高亲和性最大转运速率（Ｖｍａｘ）明显增高（５０．５６±３．２７ｐｍｏｌ／１０８ｖｓ４５．８４±２．３６ｐｍｏｌ／１０８血小板／ｍｉｎ。Ｐ＜０．０５）,米氏常数亦显著增加（２．１４±０．２３μｍｏｌ／Ｌｖｓ１．４６±０．１３μｍｏｌ／Ｌ,Ｐ＜０．０１）。应用刺激剂凝血酶和ＰＡＦ诱导运动大鼠血小板Ｌ－Ａｒｇ转运速率增加的幅度明显高于未运动对照大鼠（Ｐ＜０．０１）。实验结果表明,运动能增强血小板转运Ｌ－Ａｒｇ的效率。提示,运动可能促进血小板一氧化氮（ＮＯ）生成,抑制血小板聚集,防治血管栓塞性疾病     

一氧化氮/内皮素在大鼠胃粘膜损伤中的作用及电针的调整效应

用酒精灌胃引起大鼠胃粘膜损伤模型,观察内皮衍生因子（ＮＯ／ＥＴ）的含量变化和电针对胃粘膜损伤调整作用,结果发现：酒精灌胃后,胃粘膜血流量（ＧＭＢＦ）、跨壁电位差,血ＮＯ含量降低（Ｐ〈０．０１）,血浆ＥＴ含量和胃粘膜损伤指数（ＬＩ）增高（Ｐ〈０．０１）。Ｌ－精氨酸（Ｌ－Ａｒｇ）或硝普钠（ＳＮＰ）灌注预处理后（ｉｖ）,ＮＯ含量和ＧＭＢＦ明显升高（Ｐ〈０．０１）,ＥＴ含量和ＬＩ指数下降（Ｐ〈０．０１）。     

Restoring diabetes-induced autophagic flux arrest in ischemic/reperfused heart by ADIPOR (adiponectin receptor) activation involves both AMPK-dependent and AMPK-independent signaling

Macroautophagy/autophagy is increasingly recognized as an important regulator of myocardial ischemia-reperfusion (MI-R) injury. However, whether and how diabetes may alter autophagy in response to MI-R remains unknown. Deficiency of ADIPOQ, a cardioprotective molecule, markedly increases MI-R injury. However, the role of diabetic hypoadiponectinemia in cardiac autophagy alteration after MI-R is unclear. Utilizing normal control (NC), high-fat-diet-induced diabetes, and Adipoq knockout (adipoq^?/?) mice, we demonstrated that autophagosome formation was modestly inhibited and autophagosome clearance was markedly impaired in the diabetic heart subjected to MI-R. adipoq^?/? largely reproduced the phenotypic alterations observed in the ischemic-reperfused diabetic heart. Treatment of diabetic and adipoq^?/? mice with AdipoRon, a novel ADIPOR (adiponectin receptor) agonist, stimulated autophagosome formation, markedly increased autophagosome clearance, reduced infarct size, and improved cardiac function (P < 0.01 vs vehicle). Mechanistically, AdipoRon caused significant phosphorylation of AMPK-BECN1 (Ser93/Thr119)-class III PtdIns3K (Ser164) and enhanced lysosome protein LAMP2 expression both in vivo and in isolated adult cardiomyocytes. Pharmacological AMPK inhibition or genetic Prkaa2 mutation abolished AdipoRon-induced BECN1 (Ser93/Thr119)-PtdIns3K (Ser164) phosphorylation and AdipoRon-stimulated autophagosome formation. However, AdipoRon-induced LAMP2 expression, AdipoRon-stimulated autophagosome clearance, and AdipoRon-suppressed superoxide generation were not affected by AMPK inhibition. Treatment with MnTMPyP (a superoxide scavenger) increased LAMP2 expression and stimulated autophagosome clearance in simulated ischemic-reperfused cardiomyocytes. However, no additive effect between AdipoRon and MnTMPyP was observed. Collectively, these results demonstrate that hypoadiponectinemia impairs autophagic flux, contributing to enhanced MI-R injury in the diabetic state. ADIPOR activation restores AMPK-mediated autophagosome formation and antioxidant-mediated autophagosome clearance, representing a novel intervention effective against MI-R injury in diabetic conditions.     

应激心肌损伤的蛋白质组学研究

目的:寻找应激心肌损伤相关蛋白.方法:建立束缚应激心肌损伤模型,制备心室肌2DE蛋白样品和心肌2DE图谱,图像分析软件分析应激后蛋白表达差异点,MALDI-TOF-MS-数据库搜索鉴定蛋白质.结果:应激前后10个蛋白表达量发生改变,其中8个应激后表达显著升高,经质谱鉴定为心肌肌球蛋白、白蛋白、脂蛋白A-I前体等;2个显著降低,经质谱鉴定为线粒体能量代谢酶类和UCP3.结论:这些差异蛋白可能参与应激机体心肌损伤的发生.     

异丙肾上腺素所致心肌损伤动物模型的研究进展

目前,心血管疾病(cardiovascular disease,CVD)是最常见的导致人类死亡原因,但其发病机制和防治仍需要进一步研究。异丙肾上腺素(isoproterenol,ISO)是一种β-肾上腺素能受体激动剂,能够通过炎症反应、氧化应激、内质网应激、自噬和凋亡等直接和间接地作用于心肌组织,可以引起轻度心肌损伤、心肌梗死、心肌肥厚,甚至心力衰竭等。因此,本文从形态与功能学特征、发病机理等方面阐述ISO所致的动物心肌损伤模型的研究进展。     

Cardioprotective effect of isorhamnetin against myocardial ischemia reperfusion (I/R) injury in isolated rat heart through attenuation of apoptosis

In this study, we investigated the effects of isorhamnetin on myocardial ischaemia reperfusion (I/R) injury in Langendorff-perfused rat hearts. Isorhamnetin treatment (5, 10 and 20 μg/mL) significantly alleviated cardiac morphological injury, reduced myocardial infarct size, decreased the levels of marker enzymes (LDH and CK) and improved the haemodynamic parameters, reflected by the elevated levels of the left ventricular developed pressure (LVDP), coronary flow (CF) and the maximum up/down velocity of left ventricular pressure (+dp/dt_max). Moreover, isorhamnetin reperfusion inhibited apoptosis of cardiomyocytes in the rats subjected to cardiac I/R in a dose-dependent manner concomitant with decreased protein expression of Bax and cleaved-caspase-3, as well as increased protein expression of Bcl-2. In addition, I/R-induced oxidative stress was manifestly mitigated by isorhamnetin treatment, as showed by the decreased malondialdehyde (MDA) level and increased antioxidant enzymes activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px). These results indicated that isorhamnetin exerts a protective effect against I/R-induced myocardial injury through the attenuation of apoptosis and oxidative stress.     

Acute induction of autophagy as a novel strategy for cardioprotection

There is no question that necrosis and apoptosis contribute to cardiomyocyte death in the setting of myocardial ischemia-reperfusion. Indeed, considerable effort and resources have been invested in the development of novel therapies aimed at attenuating necrotic and apoptotic cell death, with the ultimate goal of applying these strategies to reduce infarct size and improve outcome in patients suffering acute myocardial infarction (MI) or ‘heart attack’. However, an issue that remains controversial is the role of autophagy in determining the fate of ischemic-reperfused cardiomyocytes: i.e., is induction of autophagy detrimental or protective? Recent data from our group obtained in the clinically relevant, in vivo swine model of acute MI provide novel evidence of a positive association between pharmacological upregulation of autophagy (achieved by administration of chloramphenicol succinate (CAPS)) and increased resistance to myocardial ischemia-reperfusion injury.     

3,6-(二甲氨基)-二苯并碘杂六环葡萄糖酸盐对损伤心肌细胞的保护作用

目的：观察3,6-（二甲氨基）-二苯并碘杂六环葡萄糖酸盐（IHC-93）对培养心肌细胞损伤的影响。方法：在培养的心肌细胞建立低氧／复氧损伤模型和过氧化氢损伤模型,观察心肌细胞存活率、乳酸脱氢酶（LDH活性、超氧化物歧化酶（SOD）活性、丙二醛（MDA含量,以研究IHC-93对培养心肌细胞损伤的影响。结果：10、20、40μmol／LIHC-93呈剂量依赖地提高损伤心肌细胞存活率和SOD的活性,减少LDH的释放,降低MDA含量。结论：IHC-93对损伤心肌细胞具有直接保护作用。     

The aetiology of myocardial injury after non-cardiac surgery

Recognition of myocardial injury after non-cardiac surgery is difficult, since strong analgesics (e.g. opioids) can mask anginal symptoms, and ECG abnormalities are subtle or transient. Thorough knowledge of the pathophysiological mechanisms is therefore essential. These mechanisms can be subdivided into four groups: type I myocardial infraction (MI), type II MI, non-ischaemic cardiac pathology, and non-cardiac pathology. The incidence of type I MI in patients with a clinical suspicion of perioperative acute coronary syndrome (ACS) is 45–57 %. This percentage is higher in patients with a high likelihood of MI such as patients with ST-elevation ACS. Of note, the generalisability of this statement is limited due to significant study limitations. Non-ischaemic cardiac pathology and non-cardiac pathology should not be overlooked as a cause of perioperative myocardial injury (PMI). Especially pulmonary embolism and dysrhythmias are a common phenomenon, and may convey important prognostic value. Implementation of routine postoperative troponin assessment and accessible use of minimally invasive imaging should be considered to provide adequate individualised therapy. Also, addition of preoperative imaging may improve the stratification of high-risk patients who may benefit from preoperative or perioperative interventions.     

Free fatty acid metabolism during myocardial ischemia and reperfusion

Long chain free fatty acids (FFA) are the preferred metabolic substrates of myocardium under aerobic conditions. However, under ischemic conditions long chain FFA have been shown to be harmful both clinically and experimentally. Serum levels of free fatty acids frequently are elevated in patients with myocardial ischemia. The proposed mechanisms of the detrimental effects of free fatty acids include: (1) accumulation of toxic intermediates of fatty acid metabolism, such as long chain acyl-CoA thioesters and long chain acylcarnitines, (2) inhibition of glucose utilization, particularly glycolysis, during ischemia and/or reperfusion, and (3) uncoupling of oxidative metabolism from electron transfer. The relative importance of these mechanisms remains controversial. The primary site of FFA-induced injury appears to be the sarcolemmal and intracellular membranes and their associated enzymes. Inhibitors of free fatty acid metabolism have been shown experimentally to decrease the size of myocardial infarction and lessen postischemic cardiac dysfunction in animal models of regional and global ischemia. The mechanism by which FFA inhibitors improve cardiac function in the postischemic heart is controversial. Whether the effects are dependent on decreased levels of long chain intermediates and/or enhancement of glucose utilization is under investigation. Manipulation of myocardial fatty acid metabolism may prove beneficial in the treatment of myocardial ischemia, particularly during situations of controlled ischemia and reperfusion, such as percutaneous transluminal coronary angioplasty and coronary artery bypass grafting. (Mol Cell Biochem 166: 85-94, 1997)